Compare EVAX & MODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | MODD |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 30.6M |
| IPO Year | 2021 | N/A |
| Metric | EVAX | MODD |
|---|---|---|
| Price | $3.98 | $0.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.33 | N/A |
| AVG Volume (30 Days) | 68.2K | ★ 248.4K |
| Earning Date | 11-06-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,650,000.00 | N/A |
| Revenue This Year | $128.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 132.17 | N/A |
| 52 Week Low | $1.20 | $0.28 |
| 52 Week High | $12.15 | $1.34 |
| Indicator | EVAX | MODD |
|---|---|---|
| Relative Strength Index (RSI) | 34.64 | 55.50 |
| Support Level | $3.88 | $0.44 |
| Resistance Level | $4.85 | $0.50 |
| Average True Range (ATR) | 0.36 | 0.04 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 8.13 | 47.84 |
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.